Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Heron Therapeutics (HRTX) Debt to Equity (2016 - 2025)

Heron Therapeutics' Debt to Equity history spans 5 years, with the latest figure at $7.53 for Q4 2025.

  • For Q4 2025, Debt to Equity rose 1112.25% year-over-year to $7.53; the TTM value through Dec 2025 reached $7.53, up 1112.25%, while the annual FY2025 figure was $7.53, 1112.25% up from the prior year.
  • Debt to Equity reached $7.53 in Q4 2025 per HRTX's latest filing, up from $7.22 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $7.53 in Q4 2025 to a low of -$0.89 in Q1 2025.
  • Average Debt to Equity over 3 years is $1.06, with a median of -$0.71 recorded in 2023.
  • The largest YoY upside for Debt to Equity was 1263.54% in 2025 against a maximum downside of 22.39% in 2025.
  • A 3-year view of Debt to Equity shows it stood at -$0.71 in 2023, then fell by 4.13% to -$0.74 in 2024, then surged by 1112.25% to $7.53 in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Debt to Equity are $7.53 (Q4 2025), $7.22 (Q3 2025), and -$0.89 (Q1 2025).